Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolic Predictors of Weight Loss with Topiramate in Epilepsy
NCT00236886Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- May 1998
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of topiramate in epilepsy, sponsored by Johnson & Johnson. Primary endpoints: Body Mass Index at 1 year, Lean Body Mass at 1 year and 2 more. Started May 1998; status: completed.
02
Drugs
topiramate
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT00236886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00236886.